Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.27), $0.03 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1.74 million versus the consensus estimate of $1.36 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.